专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021053173A1 METHODS FOR TRIGGERING M1 MACROPHAGE POLARIZATION 审中-公开
公开(公告)号：WO2021053173A1
公开(公告)日：2021-03-25
申请号：PCT/EP2020/076157
申请日：2020-09-18
申请人： NH THERAGUIX , INSTITUT GUSTAVE ROUSSY , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE PARIS-SACLAY
发明人： ALLOUCH, Awatef , DEUTSCH, Eric , PERFETTINI, Jean-Luc , LUX, François , TILLEMENT, Olivier
IPC分类号： A61K41/00 , A61K47/69 , A61K49/18 , A61P35/00 , A61P1/16 , A61P9/10 , A61P11/00 , A61P37/08 , A61K39/00 , A61N5/10
摘要： The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.

2. 发明申请

WO2019008040A1 METHODS FOR TREATING TUMORS 审中-公开
公开(公告)号：WO2019008040A1
公开(公告)日：2019-01-10
申请号：PCT/EP2018/068099
申请日：2018-07-04
申请人： NH THERAGUIX , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , INSTITUT GUSTAVE ROUSSY
发明人： LUX, François , TILLEMENT, Olivier , PERFETTINI, Jean-Luc , DEUTSCH, Eric , LAW, Frédéric , ALLOUCH, Awatef
IPC分类号： A61K41/00
摘要： The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.

3. 发明公开

EP3795178A1 METHODS FOR TRIGGERING M1 MACROPHAGE POLARIZATION 无效
公开(公告)号：EP3795178A1
公开(公告)日：2021-03-24
申请号：EP19306138.9
申请日：2019-09-19
申请人： NH THERAGUIX , Institut Gustave Roussy , UNIVERSITE CLAUDE BERNARD - LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- , INSERM (Institut National de la Santé et de la Recherche Médicale) , Universite Paris-Sud
发明人： ALLOUCH, Awatef , DEUTSCH, Eric , PERFETTINI, Jean-Luc , LUX, François , TILLEMENT, Olivier
IPC分类号： A61K41/00 , A61K47/69 , A61K49/18 , A61P35/00 , A61P1/16 , A61P9/10 , A61P11/00 , A61P37/08 , A61K39/00 , A61N5/10
摘要： The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.

4. 发明公开

EP3424533A1 METHODS FOR TREATING TUMORS 无效
公开(公告)号：EP3424533A1
公开(公告)日：2019-01-09
申请号：EP17305869.4
申请日：2017-07-05
申请人： NH THERAGUIX , Université Claude Bernard Lyon 1 , Centre National de la Recherche Scientifique (CNRS) , INSERM (Institut National de la Santé et de la Recherche Médicale) , Institut Gustave Roussy
发明人： LUX, François , TILLEMENT, Olivier , PERFETTINI, Jean-Luc , DEUTSCH, Eric , LAW, Frédéric , ALLOUCH, Awatef
IPC分类号： A61K41/00
摘要： The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.

6. 发明申请

WO2016092041A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS 审中-公开
标题翻译：用于治疗人免疫缺陷病毒1型（HIV-1）感染的方法和药物组合物
公开(公告)号：WO2016092041A1
公开(公告)日：2016-06-16
申请号：PCT/EP2015/079310
申请日：2015-12-10
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE PARIS-SUD , INSTITUT GUSTAVE ROUSSY , UNIVERSITÉ PARIS DESCARTES , UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) , INSTITUT PASTEUR , ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE IRCCS LAZZARO SPALLANZANI , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
发明人： KROEMER, Guido , PERFETTINI, Jean-Luc , GOUGEON, Marie-Lise , ALLOUCH, Awatef , PIACENTINI, Mauro
IPC分类号： C12N15/113 , A61K31/7088
CPC分类号： C12N15/113 , A61K31/165 , A61K31/17 , A61K31/395 , A61K31/5517 , A61K31/683 , A61K31/7088 , A61K31/713 , A61K45/06 , C12N15/1132 , C12N2310/14 , C12N2320/31 , C12Q1/18 , A61K2300/00
摘要： The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.
摘要翻译：本发明提供了用于治疗1型（HIV-1）感染的人类免疫缺陷病毒的方法和药物组合物。特别地，本发明涉及在有需要的受试者中治疗HIV-1感染的方法，包括给予受试者治疗有效量的SGT1活性抑制剂或表达。

8. 发明申请

WO2021245107A2 MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM 审中-公开
公开(公告)号：WO2021245107A2
公开(公告)日：2021-12-09
申请号：PCT/EP2021/064718
申请日：2021-06-01
申请人： INSTITUT GUSTAVE ROUSSY
发明人： PERFETTINI, Jean-Luc , LECUYER, Deborah , TANNOUS, Désirée , ALLOUCH, Awatef , DELELIS, Olivier , SUBRA, Frederic
IPC分类号： A61K31/7084 , A61K31/675 , A61K31/7072 , A61P11/00 , A61P31/14 , A61K45/06
摘要： The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.

9. 发明申请

WO2018050928A1 NOX2 AS A BIOMARKER OF RADIOTHERAPY EFFICIENCY IN CANCER PATIENTS 审中-公开
标题翻译： NOX2作为癌症患者放射治疗效果的生物标志物
公开(公告)号：WO2018050928A1
公开(公告)日：2018-03-22
申请号：PCT/EP2017/073677
申请日：2017-09-19
申请人： INSTITUT GUSTAVE-ROUSSY
发明人： PERFETTINI, Jean-Luc , DEUTSCH, Eric , ALLOUCH, Awatef
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57419 , G01N2800/52
摘要： Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. They also report that hypoxic conditions and the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, these results identify a novel signaling pathway involved in macrophage activation that may enhance effectiveness of radiotherapy through the re-programming of tumor infiltrating macrophages.
摘要翻译：虽然肿瘤相关巨噬细胞已广泛研究了放疗反应的控制，但涉及电离辐射介导的巨噬细胞活化的分子机制仍然难以捉摸。在此，本发明人表明，电离辐射诱导干扰素调节因子5（IRF5）的表达，从而促进巨噬细胞活化为促炎症表型。他们揭示，激活共济失调毛细血管扩张突变（ATM）激酶是电离辐射引起的巨噬细胞激活所必需的，而且在γ-干扰素，脂多糖或化学治疗剂（如顺铂）治疗后用于巨噬细胞重编程需要，强调事实上激酶ATM在巨噬细胞表型转换为促炎症表型过程中起着核心作用。他们进一步证明NADPH氧化酶2（NOX2）依赖性ROS产生在ATM激活的上游，并且在此过程中是必不可少的。他们还报告说，缺氧条件和这种信号通路的任何成分（NOX2，ROS和ATM）的抑制都会损害巨噬细胞的促炎激活，并预测局部晚期直肠癌术前放疗的肿瘤反应差。总之，这些结果确定了涉及巨噬细胞活化的新信号通路，其可通过重新编程肿瘤浸润巨噬细胞来提高放射疗法的有效性。

10. 发明申请

WO2021013764A1 P21 EXPRESSING MONOCYTES FOR CANCER CELL THERAPY 审中-公开
公开(公告)号：WO2021013764A1
公开(公告)日：2021-01-28
申请号：PCT/EP2020/070379
申请日：2020-07-17
申请人： INSTITUT GUSTAVE ROUSSY
发明人： PERFETTINI, Jean-Luc , ALLOUCH, Awatef , DEUTSCH, Eric
IPC分类号： A61K35/15 , C12N5/0786 , A61K39/00
摘要： Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo , delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式